Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients

Bibliographic Details
Main Authors:	Eaton, C, Wells, J, Holen, I, Croucher, P, Hamdy, F
Format:	Conference item
Published:	2004

Similar Items

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
by: Eaton, C, et al.
Published: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
by: Holen, I, et al.
Published: (2002)

Role of osteoprotegerin (OPG) in cancer.
by: Holen, I, et al.
Published: (2006)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
by: Holen, I, et al.
Published: (2002)

The role of osteoprotegerin in breast and prostate cancer
by: Holen, I, et al.
Published: (2002)

OPG is a survival factor for breast- and prostate cancer cells in vitro
by: Holen, I, et al.
Published: (2002)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
by: Miles, L, et al.
Published: (2004)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
by: Gamal B Mohamed, et al.
Published: (2011-01-01)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
by: Holen Ingunn, et al.
Published: (2009-07-01)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
by: Lili Zhang, et al.
Published: (2016-11-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
by: Riham Eid, et al.
Published: (2023-06-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
by: Indra Wijaya, et al.
Published: (2024-01-01)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
by: Shipman, C, et al.
Published: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
by: Waterman, E, et al.
Published: (2007)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
by: Shipman, C, et al.
Published: (2002)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
by: Chan Kai-Ming, et al.
Published: (2011-07-01)

Analysis of periodontal parameteres and salivary levels of Receptor Activator of NF- κβ Ligand (RANKL) and Osteoprotegerin (OPG) in obese periodontitis patients
by: Cheema, Raheem Ramzan
Published: (2021)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
by: Yao Jing, et al.
Published: (2011-03-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Serum level of osteoprotegerin in patients with Parkinson’s disease: a preliminary study
by: Marta Piaścik-Gromada, et al.
Published: (2024-03-01)

Changes of serum osteoprotegerin level in recurrent urolithiasis
by: A. V. Savilov, et al.
Published: (2023-10-01)

Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
by: F. F. Rija, et al.
Published: (2021-10-01)

Dickkopf-1 levels and serum Osteoprotegerin in women with Osteoporosis
by: Mehrzad Hajialilo, et al.
Published: (2013-12-01)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
by: Yen-Liang Chen, et al.
Published: (2023-10-01)

Serum Osteoprotegerin level and the extent of cardiovascular calcification in haemodialysis patients
by: Waleed Ammar, et al.
Published: (2014-03-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
by: Martin Widschwendter, et al.
Published: (2015-10-01)

Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis
by: Wei-Chen Lin, et al.
Published: (2020-01-01)

The influence of vitamin D administration on the clinical presentation, body mass index, and osteoprotegerin (OPG) level in a sample of Egyptian children with familial Mediterranean fever
by: Hanaa Reyad Abdallah, et al.
Published: (2021-12-01)

The Role of procollagen type 1 amino-terminal propertied (P1NP) Cytochrome P450 (CYPs) and Osteoprotegerin (OPG) as Potential Bone function markers in Prostate Cancer Bone Metastasis
by: Yousif Pshtiwan A., et al.
Published: (2023-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
by: Yosra Azizpour, et al.
Published: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
by: Yosra Azizpour, et al.
Published: (2020-01-01)

Association of OPG genotypes with their serum levels in Iraqi type 2 diabetic patients
by: Diana, et al.
Published: (2022-09-01)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
by: Lane Denis, et al.
Published: (2012-11-01)

Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells
by: Lara Absil, et al.
Published: (2021-04-01)

Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients
by: Kamal M. Okasha, et al.
Published: (2022-06-01)

SYNOVIAL AND SERUM LEVELS OF OSTEOCALCIN, OSTEOPROTEGERIN AND Β-CROSSLAPS IN PATIENTS WITH CALCIUM PYROPHOSPHATE DEPOSITION DISEASE
by: Paulina Vele, et al.
Published: (2019-06-01)